Nucleophosmin 1 (NPM1) and fms‐like tyrosine kinase 3‐internal duplication (FLT3‐ITD) mutations occur in 50% and 30% of AML patients, respectively, and have negative impact on AML prognosis.15 The gene discussed is NPM1; the disease is acute myeloid leukemia.